Scintigraphy of Pituitary Tumors

作者: Wouter W. de Herder , Diego Ferone , Dik J. Kwekkeboom , Steven W. J. Lamberts

DOI: 10.1007/978-1-4615-4341-1_3

关键词: ProlactinEndocrinologyAdrenocorticotropic hormoneHormoneThyroid-stimulating hormonePituitary tumorsHypopituitarismMedicineMalignancyInternal medicinePituitary adenoma

摘要: Several neoplastic and non-neoplastic lesions may arise within the sellar parasellar regions (Table 1). Among these, pituitary adenomas are most common. Almost all tumors benign, although they display signs of local invasion or show histological evidence malignancy. However, generally these can be designated malignant only when distant metastases present. Adenomas with a diameter less than 10 mm classified as microadenomas, whereas those greater considered macroadenomas. Pituitary subclassified into clinically functioning — according to hormone secreted non-functioning. products prolactin (PRL), growth (GH), adrenocorticotropic (ACTH), thyroid stimulating (TSH), gonadotropins (LH FSH), glycoprotein subunits (SU) mixtures products. The majority so-called macroadenomas either secrete inappropriate amounts hormones, inactive hormonal fragments. differential diagnosis is currently based on clinical, endocrinological radiological characteristics. Active hormone-secreting easily diagnosed because symptoms related hypersecretion. Clinically nonfunctioning do not produce specific syndromes, but often hypopituitarism results from insufficient secretion anterior hormones.

参考文章(63)
C. Luyken, G. Hildebrandt, B. Krisch, K. Scheidhauer, N. Klug, Clinical relevance of somatostatin receptor scintigraphy in patients with skull base tumours. Acta Neurochirurgica. ,vol. 65, pp. 102- 104 ,(1996) , 10.1007/978-3-7091-9450-8_28
Kim Neve, J. N. Joyce, Aaron Janowsky, Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain Journal of Pharmacology and Experimental Therapeutics. ,vol. 257, pp. 1253- 1263 ,(1991)
C. L. MAINI, R. SCIUTO, A. TOFANI, A. FERRAIRONI, C. M. CARAPELLA, E. OCCHIPINTI, M. MOTTOLESE, M. CRECCO, Somatostatin receptor imaging in CNS tumours using 111In-octreotide. Nuclear Medicine Communications. ,vol. 16, pp. 756- 766 ,(1995) , 10.1097/00006231-199509000-00006
I. PELLEGRINI, R. RASOLONJANAHARY, G. GUNZ, P. BERTRAND, S. DELIVET, C. P. JEDYNAK, C. KORDON, F. PEILLON, P. JAQUET, A. ENJALBERT, Resistance to bromocriptine in prolactinomas. The Journal of Clinical Endocrinology and Metabolism. ,vol. 69, pp. 500- 509 ,(1989) , 10.1210/JCEM-69-3-500
A. Colao, S. Lastoria, D. Ferone, P. Varrella, P. Marzullo, R. Pivonello, G. Cerbone, W. Acampa, M. Salvatore, G. Lombardi, The pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas Journal of Endocrinological Investigation. ,vol. 22, pp. 176- 183 ,(1999) , 10.1007/BF03343538
Carin Muhr, Mats Bergström, Per Olov Lundberg, Kjell Bergström, Per Hartvig, Hans Lundqvist, Gunnar Antoni, Bengt Långström, Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone. Journal of Computer Assisted Tomography. ,vol. 10, pp. 175- 180 ,(1986) , 10.1097/00004728-198603000-00001
Robert M. Kessler, William O. Whetsell, M. Sib Ansari, John R. Votaw, Tomas de Paulis, Jeffrey A. Clanton, Dennis E. Schmidt, N. Scott Mason, Ronald G. Manning, Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride Brain Research. ,vol. 609, pp. 237- 243 ,(1993) , 10.1016/0006-8993(93)90878-Q
Bunzo Sato, Keizo Noma, Yasuhiko Morimoto, Susumu Kishimoto, Shintaro Mori, Toru Uozumi, Masafumi Koga, Haruyoshi Nakao, Masayo Arao, Demonstration of specific dopamine receptors on human pituitary adenomas. European Journal of Endocrinology. ,vol. 114, pp. 595- 602 ,(1987) , 10.1530/ACTA.0.1140595